Retired Steelworker, or Ironworker Local Union #7 Boston
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NAFTA’s exemption may be better for AKS shareholders than expected. In 2017 Mexico, under NAFTA, exported 2.33 million vehicles to the US, an increase of 9.4 percent. That rate may now, after the exclusion, increase three fold. And guess where they have agreed to get their steel from now going forward?
US Steel (X) has already taken steps to re-open 2 mothballed plants, expected to be on line in 6 month. Looks like AKS has hinted before it would too - to meet future demand.
I’m long and may have been surprised, but I (like the news media) am on the outside, and think this is good for America.
I am long, have done my research, and see new highs for AKS, and the other steel stocks, in the near future once more factual news comes out not this political fake news.
Happy investing
AKS 30.8 million volume.
$$$$$ 11.00 price target.Slow and steady IMO
AKS bounce should start now.
AKS looks like another winner
Why the drop?
AKS Just loaded the april 06 options.@ .54
Right right show me a deal where the cash comes in not out.
Halt off ? Amerotrade shows bid & ask
ANTH we flop around here until next week run.Is my guess.Watch for good dip to buy.
OK I got it.
Just the letter you left out
Just post the letter here
ANTH Print the single letter you left out of a stock you mentioned.
HERE COMES 3.00
ANTH Looking like over 3.00 soon.Bid and ask building
ANTH might go over $3.00 today
ANTH There's the 2.90 Iwas talking about
ANTH Could be a 100% gain today.
ANTH WOW flippers are getting their faces punched off.
ANTH flippers are here.They will be crushed.imo
WOW another options bid and ask jump up.TODAY?
ANTH here comes 2.90
ANTH Resistance NOW SHES GONE GONE GONE!!!!!
ANTH 2.88 new resistance going going going
WE broke resistance.Shorts about to get KILLED imo
ANTH INVESTOR 86 are you watching?Blew by resistance
BUSTED resistance.Keep it going
ANTH OPTIONS BIDS & ASKS JUMPING.That's where the money is.
LETS BREAK $2.78 then blue sky
ANTH 13.8 Mill OUSTANDING 10.1 Million float
ANTH short term med term and long term expected results https://www.barchart.com/stocks/quotes/ANTH/opinion
GO long with options https://ih.advfn.com/p.php?pid=nmona&article=76866912
ANTH Company Summary
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company's clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren's Syndrome, Graves' Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California.
F
Phase 3 RESULT study completed patient dosing, topline data expected March 2018
The RESULT study of Sollpura in patients with EPI caused by cystic fibrosis completed dosing for the primary treatment period on February 2, 2018. The study was initiated in May 2017 and enrolled 140 patients in the United States, Europe and Israel. The primary efficacy variable will evaluate the change from baseline in coefficient of fat absorption (“CFA”) following 4 weeks of treatment with either Sollpura or Pancreaze. Patients randomized to Sollpura will then be followed for an additional 20-week extension period (total of 24 weeks on study) for longer term assessments of weight, height, BMI, and safety. Top line data will include the major primary and secondary outcome measures based on 4 weeks of comparative treatment and is expected in March.
RESULT study reported positive interim futility analyses
In December 2017 and January 2018, we reported positive outcomes of two prespecified, sequential, and separately conducted interim futility analyses for the RESULT study after approximately 25% and 50% of patients, respectively, had completed the primary treatment period. Both analyses were conducted by RESULT’s Data Monitoring Committee which is comprised of experts appointed by the Cystic Fibrosis Found
OPTIONS is where the money is. https://www.barchart.com/stocks/quotes/ANTH/options?expiration=2018-04-20
BARCHART opinion on ANTH 100% BUY https://www.barchart.com/stocks/quotes/ANTH/opinion